Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders.
The purpose of this paper is to report the outcome of a collaborative project between the Fragile X Research and Treatment Center at the Medical Investigation of Neurodevelopmental Disorders (M.I.N.D.) Institute at the University of California at Davis, the National Fragile X Foundation (NFXF), and the Centers for Disease Control and Prevention (CDC). The objective of this collaboration was to develop and disseminate protocols for genetic counseling and cascade testing for the multiple disorders associated with the fragile X mental retardation 1 (FMR1) mutation. Over the last several years, there has been increasing insight into the phenotypic range associated with both the premutation and the full mutation of the FMR1 gene. To help develop recommendations related to screening for fragile X-associated disorders, four, two day advisory focus group meetings were conducted, each with a different theme. The four themes were: (1) fragile X-associated tremor/ataxia syndrome (FXTAS); (2) premature ovarian failure (POF) and reproductive endocrinology; (3) psychiatric, behavioral and psychological issues; and (4) population screening and related ethical issues.
McConkie-Rosell
Allyn
A
Duke University Medical Center, Durham, NC, USA. mccon006@mc.duke.edu
Abrams
Liane
L
Finucane
Brenda
B
Cronister
Amy
A
Gane
Louise W
LW
Coffey
Sarah M
SM
Sherman
Stephanie
S
Nelson
Lawrence M
LM
Berry-Kravis
Elizabeth
E
Hessl
David
D
Chiu
Sufen
S
Street
Natalie
N
Vatave
Ajay
A
Hagerman
Randi J
RJ
D017144:Focus Groups; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics; D005600:Fragile X Syndrome / Q000175:diagnosis* / Q000235:genetics; D005817:Genetic Counseling; D005820:Genetic Testing; D006801:Humans; D008487:Medical History Taking; D009154:Mutation
D051860:Fragile X Messenger Ribonucleoprotein 1; C497683:FMR1 protein, human